USA flag logo/image

An Official Website of the United States Government

Novel Glioblastoma Therapeutics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85417
Program Year/Program:
2007 / STTR
Agency Tracking Number:
CA126020
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TERPENOID THERAPEUTICS, INC.
2501 Crosspark Road Room B126-MTF Coralville, IA 52241-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Novel Glioblastoma Therapeutics
Agency: HHS
Contract: 1R41CA126020-01
Award Amount: $109,860.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schweinfurthin family of antiproliferative agents. These agents are highly toxic to CNS derived tumor cell lines in vitro and more importantly appear to exhibit this activity via a novel cellular target(s). The schweinfurthins also contain chemical functional groups which should facilitate cerebrovascular barrier pene tration, a very important aspect of drugs aimed at treating primary brain cancers. Phase One of these studies is comprised of three narrowly focused aims directed at proving the feasibility of finding advancing? a therapeutic lead from this family: These a ims include: 1) synthesis of analogs of the schweinfurthins bearing functional groups designed to improve the drug-like nature of the compounds; 2) improvement of the published synthesis of the hexahydroxanthene core of the 3-deoxyschweinfurthin motif to allow for more efficient and safe production of larger quantities of material for Phase Two studies; and 3) biological studies aimed at elucidation of the cellular or molecular target of the schweinfurthins. These aims will allow a decision to be made abo ut feasibility of studying these drugs further in pre-clinical animal models as part of Phase Two, and ultimately of bringing drugs based on this unique and potent family of compounds into use against brain cancer.

Principal Investigator:

Jeffrey D. Neighbors
3193351467
JEFFREY-NEIGHBORS@UIOWA.EDU

Business Contact:


jeffrey-neighbors@uiowa.edu
Small Business Information at Submission:

TERPENOID THERAPEUTICS, INC.
2501 Crosspark Road Room B126-MTF Coralville, IA 52241

EIN/Tax ID: 120363140
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF IOWA
UNIVERSITY OF IOWA
IOWA CITY, IA 52242-3364
RI Type: Nonprofit college or university